scholarly journals Magnetic Resonance Hippocampal Subfield Volumetric Analysis for Differentiating among Healthy Older Adults and Older Adults with Mild Cognitive Impairment or Major Depressive Disorder

2021 ◽  
Vol 73 (12) ◽  
pp. 786-792
Author(s):  
Doonyaporn Wongsawaeng ◽  
Orasa Chawalparit ◽  
Siriwan Piyapittayanan ◽  
Tanyaluck Thientunyakit ◽  
Weerasak Muangpaisan ◽  
...  

Objective: Depression among older adults is frequently an early symptom of cognitive decline, and is believed to be a risk factor for Alzheimer’s disease (AD). Hippocampal subfield volume loss is found in both mild cognitive impairment (MCI) and major depressive disorder (MDD). We aimed to investigate the potential of MR hippocampal subfield volumetry for discriminating among healthy older adults (HOA) and older adults with MCI or MDD. Materials and Methods: Seventy age-matched subjects (29 non-depressed MCI, 12 MDD, and 29 HOA) underwent 3-Tesla MR imaging (MRI) with high-resolution 3D-T1W-TFE whole brain. Hippocampal subfield volumetric measurements were performed using FreeSurfer software to distinguish among MCI, MDD, and HOA. Subgroup analysis with amyloid PET result was also performed.Results: Significantly smaller bilateral hippocampal tail volume was observed in MCI compared to HOA (p=0.004 and p=0.04 on the left and right side, respectively). The same comparative finding was observed at left HATA (hippocampus-amygdala-transition-area) of MCI (p=0.046). Other regions showed non-significantly smaller size in MCI than in HOA [left molecular layer HP (p=0.06), left whole hippocampus (p=0.06), and left CA1 (p=0.07)]. There was a non-significant trend toward smaller size in almost all 13 subfield hippocampal regions of MCI compared to MDD, even in subgroup analysis with amyloid PET result.Conclusion: MR hippocampal subfield volumetry may have value in routine clinical practice for screening individuals with MCI, and may be a valuable adjunct to amyloid PET study for very early-stage diagnosis of AD.

2019 ◽  
Vol 27 (3) ◽  
pp. S132-S133
Author(s):  
Wael Karameh ◽  
Ines Kortebi ◽  
Sanjeev Kumar ◽  
Damien Gallagher ◽  
Angela Golas ◽  
...  

Brain ◽  
2018 ◽  
Vol 141 (12) ◽  
pp. 3457-3471 ◽  
Author(s):  
Jiayuan Xu ◽  
Qiaojun Li ◽  
Wen Qin ◽  
Mulin Jun Li ◽  
Chuanjun Zhuo ◽  
...  

Abstract Depression increases the conversion risk from amnestic mild cognitive impairment to Alzheimer’s disease with unknown mechanisms. We hypothesize that the cumulative genomic risk for major depressive disorder may be a candidate cause for the increased conversion risk. Here, we aimed to investigate the predictive effect of the polygenic risk scores of major depressive disorder-specific genetic variants (PRSsMDD) on the conversion from non-depressed amnestic mild cognitive impairment to Alzheimer’s disease, and its underlying neurobiological mechanisms. The PRSsMDD could predict the conversion from amnestic mild cognitive impairment to Alzheimer’s disease, and amnestic mild cognitive impairment patients with high risk scores showed 16.25% higher conversion rate than those with low risk. The PRSsMDD was correlated with the left hippocampal volume, which was found to mediate the predictive effect of the PRSsMDD on the conversion of amnestic mild cognitive impairment. The major depressive disorder-specific genetic variants were mapped into genes using different strategies, and then enrichment analyses and protein–protein interaction network analysis revealed that these genes were involved in developmental process and amyloid-beta binding. They showed temporal-specific expression in the hippocampus in middle and late foetal developmental periods. Cell type-specific expression analysis of these genes demonstrated significant over-representation in the pyramidal neurons and interneurons in the hippocampus. These cross-scale neurobiological analyses and functional annotations indicate that major depressive disorder-specific genetic variants may increase the conversion from amnestic mild cognitive impairment to Alzheimer’s disease by modulating the early hippocampal development and amyloid-beta binding. The PRSsMDD could be used as a complementary measure to select patients with amnestic mild cognitive impairment with high conversion risk to Alzheimer’s disease.


2017 ◽  
Vol 13 (7S_Part_21) ◽  
pp. P1017-P1018 ◽  
Author(s):  
Ana Paula Mendes-Silva ◽  
Breno Satler Diniz ◽  
Gesiane Thamire Tolentino Araújo ◽  
Eduardo de Souza Nicolau ◽  
Kelly Silva Pereira ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document